298 related articles for article (PubMed ID: 11235821)
21. Interventions for erythema nodosum leprosum.
Van Veen NH; Lockwood DN; van Brakel WH; Ramirez J; Richardus JH
Cochrane Database Syst Rev; 2009 Jul; (3):CD006949. PubMed ID: 19588412
[TBL] [Abstract][Full Text] [Related]
22. Thalidomide in the treatment of leprosy.
Teo S; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD
Microbes Infect; 2002 Sep; 4(11):1193-202. PubMed ID: 12361920
[TBL] [Abstract][Full Text] [Related]
23. Adverse events in patients with leprosy on treatment with thalidomide.
Drummond PLM; Santos RMMD; Carvalho GO; Pádua CAM
Rev Soc Bras Med Trop; 2019 Apr; 52():e20180385. PubMed ID: 30994805
[TBL] [Abstract][Full Text] [Related]
24. Thalidomide approved.
Posit Aware; 1998; 9(5):16. PubMed ID: 11365882
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide--the story goes on...
Learned J
Notes Undergr; 1998; (No 37):1, 7, 9. PubMed ID: 11365815
[TBL] [Abstract][Full Text] [Related]
26. A case series of 48 patients treated with thalidomide.
Doherty SD; Hsu S
J Drugs Dermatol; 2008 Aug; 7(8):769-73. PubMed ID: 18720694
[TBL] [Abstract][Full Text] [Related]
27. Thalidomide dose proportionality assessment following single doses to healthy subjects.
Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD
J Clin Pharmacol; 2001 Jun; 41(6):662-7. PubMed ID: 11402635
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide: a re-look.
Grover JK; Vats V; Gopalakrishna R; Ramam M
Natl Med J India; 2000; 13(3):132-41. PubMed ID: 11558112
[TBL] [Abstract][Full Text] [Related]
29. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
[TBL] [Abstract][Full Text] [Related]
30. [New indications for thalidomide?].
Tuinmann G; Hegewisch-Becker S; Hossfeld DK
Dtsch Med Wochenschr; 2001 Oct; 126(42):1178-82. PubMed ID: 11607859
[No Abstract] [Full Text] [Related]
31. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century.
Annas GJ; Elias S
Am J Public Health; 1999 Jan; 89(1):98-101. PubMed ID: 9987477
[TBL] [Abstract][Full Text] [Related]
32. Theoretical basis for the activity of thalidomide.
Meierhofer C; Dunzendorfer S; Wiedermann CJ
BioDrugs; 2001; 15(10):681-703. PubMed ID: 11604049
[TBL] [Abstract][Full Text] [Related]
33. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017.
Dores GM; Bryant-Genevier M; Perez-Vilar S
JAMA Netw Open; 2019 Aug; 2(8):e199249. PubMed ID: 31411714
[TBL] [Abstract][Full Text] [Related]
34. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition.
Costa PDSS; Fraga LR; Kowalski TW; Daxbacher ELR; Schuler-Faccini L; Vianna FSL
Acta Trop; 2018 Jul; 183():134-141. PubMed ID: 29474830
[TBL] [Abstract][Full Text] [Related]
35. A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report.
Chen B; Restaino J; Norris L; Xirasagar S; Qureshi ZP; McKoy JM; Lopez IS; Trenery A; Murday A; Kahn A; Mattison DR; Ray P; Sartor O; Bennett CL
J Oncol Pract; 2012 Nov; 8(6):e158-67. PubMed ID: 23598851
[TBL] [Abstract][Full Text] [Related]
36. Role of azathioprine in preventing recurrences in a patient of recurrent erythema nodosum leprosum.
Verma KK; Srivastava P; Minz A; Verma K
Lepr Rev; 2006 Sep; 77(3):225-9. PubMed ID: 17172003
[TBL] [Abstract][Full Text] [Related]
37. Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial.
de Barros B; Lambert SM; Shah M; Pai VV; Darlong J; Rozario BJ; Alinda MD; Sales AM; Doni S; Hagge DA; Shrestha D; Listiawan MY; Yitaye AM; Nery JAC; Neupane KD; Dias VLA; Butlin CR; Nicholls PG; Lockwood D; Walker SL
BMJ Open; 2020 Nov; 10(11):e037700. PubMed ID: 33203627
[TBL] [Abstract][Full Text] [Related]
38. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
Davies M; Wilton L; Shakir S
Drug Saf; 2013 Apr; 36(4):237-46. PubMed ID: 23483377
[TBL] [Abstract][Full Text] [Related]
39. A review of thalidomide's history and current dermatological applications.
Perri AJ; Hsu S
Dermatol Online J; 2003 Aug; 9(3):5. PubMed ID: 12952752
[TBL] [Abstract][Full Text] [Related]
40. Twenty Years of Targeted and Biologic Immunomodulatory Drugs: Postmarketing Modifications of Drug Labels Approved by the US Food and Drug Administration.
Berman J; Yavne Y; Edel Y; Elkayam O; Furer V; Shepshelovich D
Mayo Clin Proc; 2022 Aug; 97(8):1512-1522. PubMed ID: 35933136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
